arry-502
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2011 (NCT01349725)
Timeline
Indications
Studied for
Mechanism of action
- G protein-coupled receptor 44ANTAGONIST
PTGDR2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(Cl)ccc1CCNC(=O)c1ccc(Oc2cc3c(cc2Cl)[C@@H](C(=O)O)CCO3)cc1- Mol. weight
- 516.38 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314403 ↗
- ChEMBLCHEMBL3545109 ↗
Also known as
- arry-502
- arry-502
- arry-502
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01561690 | Phase 2 | Mar 1, 2012 | Array BioPharma |
| NCT01349725 | Phase 1 | May 1, 2011 | Array BioPharma |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Array BioPharma | For profit | 2 | 2 | 2 | 2011 |
1 organizations
Page 1 / 1